DS
INO icon

David Shaw’s Inovio Pharmaceuticals INO Stock Holding History

David Shaw’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,333
Closed -$928K – 4866
2021
Q1 		$928K Buy
+8,333
New +$1.1M ﹤0.01% 3176

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

David Shaw's INO Position: Q2 2026 in Review

David Shaw reduced its Inovio Pharmaceuticals (INO) stake by 39% in Q2 2026, selling an estimated $1.02M and leaving 1,351,656 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3449.

David Shaw first reported a position in INO in Q4 2014 and has held it in 39 quarters since. The position peaked at $29.9M in Q4 2021. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • David Shaw held 1,351,656 shares of Inovio Pharmaceuticals worth $1.49M as of Q2 2026.
  • David Shaw sold 861,163 Inovio Pharmaceuticals shares in Q2 2026, an estimated $1.02M.
  • Inovio Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3449 holding.
  • David Shaw first reported a position in Inovio Pharmaceuticals in Q4 2014 and has held it in 39 quarters since.
  • David Shaw's Inovio Pharmaceuticals position peaked at $29.9M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.